Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Image source: Getty Images. Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will ...

Is Regeneron stock a buy now? Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China’s Hansoh Pharmaceuticals 3692.HK. By licensing a drug in ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

The EMA has issued a new guideline on how to include and/or retain pregnant and breastfeeding women in clinical trials, in a move that it says “marks a change in the paradigm.” The aim is to ensure ...